Table 1. Baseline characteristics of the total IHCC patients.
| Characteristics | Number (%) | |
|---|---|---|
| Follow-up duration | Median (range) | 82.09 (1.28–140.35) |
| Age | Median (range) | 60 (31–91) |
| Sex | Male | 61 (70.1) |
| T stage* | 1 | 37 (42.5) |
| 2 | 21 (24.1) | |
| 3 | 19 (21.8) | |
| 4 | 10 (11.5) | |
| N stage1 | 1 | 23 (36.5) |
| M stage | 1 | 5 (5.8) |
| CA19-92 | > 37 U/mL | 41 (50.6) |
| Total bilirubin level | Median (range) | 0.6 (0.2–12.2) |
| HBsAg | + | 18 (20.7) |
| Anti-HBs | + | 47 (54.0) |
| Anti-HBc3 | + | 68 (84.0) |
| Anti-HCV4 | + | 3 (3.5) |
| Liver cirrhosis | + | 13 (14.9) |
| History of CBD stone | + | 3 (3.5) |
| History of GB stone | + | 7 (8.1) |
*7th AJCC TNM staging system, missing data: 1; n = 24, 2; n = 6, 3; n = 6; 4; n = 1
Common bile duct stone, CBD; gallbladder, GB.